{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T23:10:33Z","timestamp":1773702633078,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To assess the characteristics and long-term outcomes of adult patients with dysthyroid optic neuropathy (DON) who underwent orbital decompression surgery and\/or received intravenous (IV) methylprednisolone.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Retrospective chart review of 98 eyes of 49 patients who were diagnosed and treated with bilateral DON between 2007 and 2018 at the Department of Ophthalmology and Optometry and Oral and Maxillofacial Surgery of the Medical University of Vienna.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The mean follow-up period was 4.1\u2009\u00b1\u20092.7\u00a0years. The most common presenting symptoms were eyelid and periorbital swelling (45%) representing active inflammation. Upgaze restriction was the most common clinical finding (73%). At time of diagnosis, the mean clinical activity score was 4\u2009\u00b1\u20091\/4\u2009\u00b1\u20091 (right\/left eye, respectively). Sixty-three percent (31\/49) of the patients were treated both with IV methylprednisolone and underwent orbital decompression surgery, 22% (11\/49) were treated with IV methylprednisolone alone and 14% (7\/49) underwent surgical decompression only. Seventy-one percent (30\/42) of the patients underwent 3-wall decompression. The mean reduction of proptosis in patients treated with both IV methylprednisolone and orbital decompression surgery was 4\/5\u00a0mm. Mean of reduction in proptosis in patients receiving IV methylprednisolone only was 1\/0\u00a0mm and in patients with surgical decompression only was 5\/5\u00a0mm. Mean VA was 0.1\u2009\u00b1\u20090.5\/0.1\u2009\u00b1\u20090.5 logMAR at baseline and 0.05\u2009\u00b1\u20090.7\/0.05\u2009\u00b1\u20090.7 at final follow-up. In 92% (45\/49), VA was preserved or improved at final follow-up.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The majority of patients with DON were treated both with IV corticosteroids and 3-wall decompression surgery. Vision could be successfully preserved in most cases and reduction of proptosis was achieved, especially after orbital decompression surgery.<\/jats:p>\n                \n              <\/jats:sec>","DOI":"10.1007\/s00417-022-05732-4","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T08:14:49Z","timestamp":1655885689000},"page":"3683-3691","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Management of patients with dysthyroid optic neuropathy treated with intravenous corticosteroids and\/or orbital decompression surgery"],"prefix":"10.1007","volume":"260","author":[{"given":"Sandra","family":"Rezar-Dreindl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Papp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnulf","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Neumayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Eibenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Stifter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ursula","family":"Schmidt-Erfurth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,22]]},"reference":[{"key":"5732_CR1","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1056\/NEJMra1510030","volume":"375","author":"TJ Smith","year":"2016","unstructured":"Smith TJ, Heged\u00fcs L (2016) Graves\u2019 disease. N Engl J Med 375:1552\u20131565","journal-title":"N Engl J Med"},{"key":"5732_CR2","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1210\/jc.2012-3119","volume":"98","author":"KA Ponto","year":"2013","unstructured":"Ponto KA, Merkesdal S, Hommel G, Pitz S, Pfeiffer N, Kahaly GJ (2013) Public health relevance of Graves\u2019 orbitopathy. J Clin Endocrinol Metab 98:145\u2013152","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"5732_CR3","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13023-017-0625-1","volume":"12","author":"P Perros","year":"2017","unstructured":"Perros P, Heged\u00fcs L, Bartalena L, Marcocci C, Kahaly GJ, Baldeschi L et al (2017) Graves\u2019 orbitopathy as a rare disease in Europe: a European Group on Graves\u2019 Orbitopathy (EUGOGO) Position Statement. Orphanet J Rare Dis 12(1):72","journal-title":"Orphanet J Rare Dis"},{"key":"5732_CR4","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2169\/internalmedicine.53.1518","volume":"53","author":"Y Hiromatsu","year":"2014","unstructured":"Hiromatsu Y, Eguchi H, Tani J, Kasaoka M, Teshima Y (2014) Graves\u2019 ophthalmopathy: epidemiology and natural history. Intern Med 53:353\u2013360","journal-title":"Intern Med"},{"key":"5732_CR5","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.beem.2011.11.001","volume":"26","author":"WM Wiersinga","year":"2012","unstructured":"Wiersinga WM (2012) Quality of life in Graves\u2019 ophthalmopathy. Best Pract Res Clin Endocrinol Metab 26:359\u2013370","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"5732_CR6","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/S0161-6420(88)32978-7","volume":"95","author":"JM Neigel","year":"1988","unstructured":"Neigel JM, Rootman J, Belkin RI et al (1988) Dysthyroid optic neuropathy. The crowded orbital apex syndrome. Ophthalmology 95:1515\u20131521","journal-title":"Ophthalmology"},{"key":"5732_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1080\/17469899.2017.1276444","volume":"12","author":"AD Blandford","year":"2017","unstructured":"Blandford AD, Zhang D, Chundury RV, Perry JD (2017) Dysthyroid optic neuropathy: update on pathogenesis, diagnosis, and management. Expert Rev Ophthalmol 12:111\u2013121","journal-title":"Expert Rev Ophthalmol"},{"key":"5732_CR8","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41433-021-01504-2","volume":"36","author":"A Garip Kuebler","year":"2022","unstructured":"Garip Kuebler A, Halfter K, Reznicek L, Klingenstein A, Priglinger S, Hintschich C (2022) Evaluating the interreader agreement and intrareader reproducibility of visual field defects in thyroid eye disease- compressive optic neuropathy. Eye (Lond) 36:724\u2013732","journal-title":"Eye (Lond)"},{"key":"5732_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/IIO.0000000000000101","volume":"56","author":"AJ Victores","year":"2016","unstructured":"Victores AJ, Takashima M (2016) Thyroid eye disease: optic neuropathy and orbital decompression. Int Ophthalmol Clin 56:69\u201379","journal-title":"Int Ophthalmol Clin"},{"key":"5732_CR10","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1097\/IOP.0000000000001136","volume":"34","author":"M Marin\u00f2","year":"2018","unstructured":"Marin\u00f2 M, Menconi F, Dottore GR, Leo M, Marcocci C (2018) Selenium in Graves hyperthyroidism and orbitopathy. Ophthalmic Plast Reconstr Surg 34:105\u2013110","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"5732_CR11","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1055\/s-0035-1554721","volume":"47","author":"M Salvi","year":"2015","unstructured":"Salvi M, Campi I (2015) Medical treatment of Graves\u2019 orbitopathy. Horm Metab Res 47:779\u2013788","journal-title":"Horm Metab Res"},{"key":"5732_CR12","doi-asserted-by":"publisher","first-page":"G43","DOI":"10.1530\/EJE-21-0479","volume":"185","author":"L Bartalena","year":"2021","unstructured":"Bartalena L, Kahaly GJ, Baldeschi L et al (2021) The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy. Eur J Endocrinol 185:G43\u2013G67","journal-title":"Eur J Endocrinol"},{"key":"5732_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1080\/01676830.2019.1600150","volume":"39","author":"VS Starks","year":"2020","unstructured":"Starks VS, Reinshagen KL, Lee NG, Freitag SK (2020) Visual field and orbital computed tomography correlation in dysthyroid optic neuropathy due to thyroid eye disease. Orbit 39:77\u201383","journal-title":"Orbit"},{"key":"5732_CR14","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.survophthal.2017.03.007","volume":"63","author":"DB Rootman","year":"2018","unstructured":"Rootman DB (2018) Orbital decompression for thyroid eye disease. Surv Ophthalmol Jan-Feb 63:86\u2013104","journal-title":"Surv Ophthalmol Jan-Feb"},{"key":"5732_CR15","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1089\/thy.2013.0445","volume":"24","author":"N Curr\u00f2","year":"2014","unstructured":"Curr\u00f2 N, Covelli D, Vannucchi G et al (2014) Therapeutic outcomes of high-dose intravenous steroids in the treatment of dysthyroid optic neuropathy. Thyroid 24:897\u2013905","journal-title":"Thyroid"},{"key":"5732_CR16","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41433-018-0259-0","volume":"33","author":"AA Tooley","year":"2019","unstructured":"Tooley AA, Godfrey JK, Kazim M (2019) Evolution of thyroid eye disease decompression-dysthyroid optic neuropathy. Eye (Lond) 33:206\u2013211","journal-title":"Eye (Lond)"},{"key":"5732_CR17","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1136\/bjo.2006.094607","volume":"91","author":"D McKeag","year":"2007","unstructured":"McKeag D, Lazarus JH, Baldeschi L et al (2007) Clinical features of dysthyroid optic neuropathy: a European Group on Graves\u2019 Orbitopathy (EUGOGO) Survey. Br J Ophthalmol 91:455\u2013458","journal-title":"Br J Ophthalmol"},{"key":"5732_CR18","doi-asserted-by":"publisher","first-page":"349","DOI":"10.15557\/JoU.2018.0051","volume":"18","author":"M Karolczak-Kulesza","year":"2018","unstructured":"Karolczak-Kulesza M, Rudyk M, Niestrata-Ortiz M (2018) Recommendations for ultrasound examination in ophthalmology. Part II: Orbital ultrasound. J Ultrason 18:349\u2013354","journal-title":"J Ultrason"},{"key":"5732_CR19","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1159\/000486828","volume":"7","author":"B Rutkowska-Hinc","year":"2018","unstructured":"Rutkowska-Hinc B, Maj E, Jab\u0142o\u0144ska A, Milczarek-Banach J, Bednarczuk T, Mi\u015bkiewicz P (2018) Prevalence of radiological signs of dysthyroid optic neuropathy in magnetic resonance imaging in patients with active, moderate-to-severe, and very severe graves orbitopathy. Eur Thyroid J 7:88\u201389","journal-title":"Eur Thyroid J"},{"key":"5732_CR20","doi-asserted-by":"publisher","first-page":"5234","DOI":"10.1210\/jc.2005-0148","volume":"90","author":"GJ Kahaly","year":"2005","unstructured":"Kahaly GJ, Pilz S, Hommel G, Dittmar M (2005) Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves\u2019 orbitopathy. J Clin Endocrinol Metab 90:5234\u20135240","journal-title":"J Clin Endocrinol Metab"},{"key":"5732_CR21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000443828","volume":"5","author":"L Bartalena","year":"2016","unstructured":"Bartalena L, Baldeschi L, Boboridis K et al (2016) European Group on Graves\u2019 Orbitopathy (EUGOGO) The 2016 European Thyroid Association\/European Group on Graves\u2019 Orbitopathy guidelines for the management of Graves\u2019 orbitopathy. Eur Thyroid J 5:9\u201326","journal-title":"Eur Thyroid J"},{"key":"5732_CR22","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1001\/archopht.116.12.1618","volume":"116","author":"RA Goldberg","year":"1998","unstructured":"Goldberg RA, Kim AJ, Kerivan KM (1998) The lacrimal keyhole, orbital door jamb, and basin of the inferior orbital fissure: three areas of deep bone in the lateral orbit. Arch Ophthalmol 116:1618\u20131624","journal-title":"Arch Ophthalmol"},{"key":"5732_CR23","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1038\/s41433-018-0144-x","volume":"32","author":"Y Wong","year":"2018","unstructured":"Wong Y, Dickinson J, Perros P et al (2018) A British Ophthalmological Surveillance Unit (BOSU) Study into dysthyroid optic neuropathy in the United Kingdom. Eye (Lond) 32:1555\u20131562","journal-title":"Eye (Lond)"},{"key":"5732_CR24","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/archopht.1993.01090020051022","volume":"111","author":"DL Lippa","year":"1993","unstructured":"Lippa DL, Rootman J (1993) The initial clinical characteristics of Graves\u2019 orbitopathy vary with age and sex. Arch Ophthalmol 111:197\u2013201","journal-title":"Arch Ophthalmol"},{"key":"5732_CR25","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.1210\/jc.2005-2813","volume":"91","author":"A Eckstein","year":"2006","unstructured":"Eckstein A, Plicht M, Lax H et al (2006) Thyrotropin receptor autoantibodies are independent risk factors for Graves\u2019 ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 91:3464\u20133470","journal-title":"J Clin Endocrinol Metab"},{"key":"5732_CR26","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1365-2265.2005.02345.x","volume":"63","author":"IM Wakelkamp","year":"2005","unstructured":"Wakelkamp IM, Baldeschi L, Saeed P, Mourits MP, Prummel MF, Wiersinga WM (2005) Surgical or medical decompression as a first-line treatment of optic neuropathy in Graves\u2019 ophthalmopathy? A randomized controlled trial. Clin Endocrinol 63:323\u2013328","journal-title":"Clin Endocrinol"},{"key":"5732_CR27","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/eye.2017.260","volume":"32","author":"JM Jefferis","year":"2018","unstructured":"Jefferis JM, Jones RK, Currie ZI, Tan JH, Salvi M (2018) Orbital decompression for thyroid eye disease: methods, outcomes, and complications. Eye (Lond) 32:626\u2013636","journal-title":"Eye (Lond)"},{"key":"5732_CR28","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.18240\/ijo.2019.11.12","volume":"12","author":"Y Wen","year":"2016","unstructured":"Wen Y, Yan JH (2016) The effect of intravenous high-dose glucocorticoids and orbital decompression surgery on sight-threatening thyroid-associated ophthalmopathy. Int J Ophthalmol 12:1737\u20131745","journal-title":"Int J Ophthalmol"},{"key":"5732_CR29","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3109\/02713683.2015.1008641","volume":"41","author":"S Korkmaz","year":"2016","unstructured":"Korkmaz S, Konuk O (2016) Surgical treatment of dysthyroid optic neuropathy: long-term visual outcomes with comparison of 2-wall versus 3-wall orbital decompression. Curr Eye Res 41:159\u2013164","journal-title":"Curr Eye Res"},{"key":"5732_CR30","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.joms.2006.01.024","volume":"64","author":"H Cansiz","year":"2006","unstructured":"Cansiz H, Yilmaz S, Karaman E et al (2006) Three-wall orbital decompression superiority to 2-wall orbital decompression in thyroid-associated ophthalmopathy. J Oral Maxillofac Surg 64:763\u2013769","journal-title":"J Oral Maxillofac Surg"},{"key":"5732_CR31","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/01.IOP.0000092796.43025.B1","volume":"19","author":"AAV Cruz","year":"2003","unstructured":"Cruz AAV, Leme VR (2003) Orbital decompression: a comparison between trans-fornix\/transcaruncular inferomedial and coronal inferomedial plus lateral approaches. Ophthal Plast Reconstr Surg 19:440\u2013445","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"5732_CR32","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1111\/aos.13135","volume":"94","author":"OH Haugen","year":"2016","unstructured":"Haugen OH, R\u00f8dahl E (2016) Temporal hollowing and other adverse effects after lateral orbital wall decompression. Acta Ophthalmol 94:793\u2013797","journal-title":"Acta Ophthalmol"},{"key":"5732_CR33","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1210\/jc.2014-2572","volume":"100","author":"MN Stan","year":"2015","unstructured":"Stan MN, Garrity JA, Carranza Leon BG, Prabin T, Bradley EA, Bahn RS (2015) Randomized controlled trial of rituximab in patients with Graves\u2019 orbitopathy. J Clin Endocrinol Metab 100:432\u2013441","journal-title":"J Clin Endocrinol Metab"},{"key":"5732_CR34","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","volume":"376","author":"TJ Smith","year":"2017","unstructured":"Smith TJ, Kahaly GJ, Ezra DG et al (2017) Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med 376:1748","journal-title":"N Engl J Med"},{"key":"5732_CR35","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1136\/bjo.87.6.773","volume":"87","author":"A Eckstein","year":"2003","unstructured":"Eckstein A, Quadbeck B, Mueller G et al (2003) Impact of smoking on the response to treatment of thyroid associated ophthalmopathy. Br J Ophthalmol 87:773\u2013776","journal-title":"Br J Ophthalmol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-022-05732-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-022-05732-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-022-05732-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T18:07:07Z","timestamp":1666202827000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-022-05732-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,22]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["5732"],"URL":"https:\/\/doi.org\/10.1007\/s00417-022-05732-4","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,22]]},"assertion":[{"value":"26 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the ethics committee of the Medical University of Vienna and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}